Antitumor cytostatic doxorubicin in liposomal form does not have a damaging effect on mitochondria
- Autores: Nikitina E.R1, Korotkov S.M1, Petunov S.G1, Vasileva K.A1, Mindukshev I.V1, Krivchenko A.I1
-
Afiliações:
- Sechenov Institute of evolutionary physiology and biochemistry RAS
- Edição: Volume 14, Nº 3 (2019)
- Páginas: 85-86
- Seção: Articles
- ##submission.dateSubmitted##: 16.01.2023
- ##submission.datePublished##: 15.09.2019
- URL: https://genescells.ru/2313-1829/article/view/122419
- DOI: https://doi.org/10.23868/gc122419
- ID: 122419
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Texto integral
Sobre autores
E. Nikitina
Sechenov Institute of evolutionary physiology and biochemistry RAS
Email: elena.nikitina@bk.ru
St. Petersburg, Russia
S. Korotkov
Sechenov Institute of evolutionary physiology and biochemistry RASSt. Petersburg, Russia
S. Petunov
Sechenov Institute of evolutionary physiology and biochemistry RASSt. Petersburg, Russia
K. Vasileva
Sechenov Institute of evolutionary physiology and biochemistry RASSt. Petersburg, Russia
I. Mindukshev
Sechenov Institute of evolutionary physiology and biochemistry RASSt. Petersburg, Russia
A. Krivchenko
Sechenov Institute of evolutionary physiology and biochemistry RASSt. Petersburg, Russia
Bibliografia
- Forrancs V.J. Overview of cardiac pathology in relation to anthracydine cardiac toxicity. Canc. Treat. Rep. 1978; 62: 955-61.
- Olson R.D., Mushlin P.S., Brenner D.E. et al. Doxorubicin cardio-toxicity may be caused by its metabolite, doxorubicinol. PNAS USA 1988; 85(10): 3585-9.
- Harrington K.L., Lewanski C.R., Stewart S.W. Liposomes as vehicles for targeted therapy of cancer. Part 2: Clinical development. Clin. Oncol. 2000; 12: 16-24.
Arquivos suplementares
